Biomarker-Oriented Contextual Analysis of First-Line Zolbetuximab and Immunotherapy-Based Strategies in HER2-Negative Metastatic Gastric Cancer. (PubMed, Oncology) - Sep 10, 2026 - "Without direct comparative data, treatment selection in CLDN18.2-positive, PD-L1 CPS-low disease requires integration of biomarker biology and clinical context. This biomarker-informed framework supports clinical decision-making under uncertainty."
Biomarker • IO biomarker • Journal • Gastric Cancer • Microsatellite Instability • Oncology • Solid Tumor • CLDN18 • HER-2 • MSI • PD-L1
|
|
Arianna Sabatini; Elisabetta Bengala; Vincenzo Picone
|